Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand

The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Buriram, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Established persistent asthma
Currently treated with Symbicort SMART for 3 months or longer

Exclusion criteria

currently participating or have participated in a study with an investigational compound within the last 30 days
current diagnosis of chronic obstructive pulmonary disease (COPD)
smoked more than 10 pack-year

Treatment and study plan

Primary outcomes

Number of budesonide/formoterol use per patient

Time frame: On the survey date

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Budesonide/Formoterol for Maintenance and Reliever Therapy: A Medication Use Evaluation Among Persistent Asthma Patients in General Practice in Thailand

Important dates

Study start: 2009
Study completion: 2009
First posted: Dec 2, 2008
Registry last updated: Dec 3, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed